/INDEX.ST
INDEX.ST Stock - InDex Pharmaceuticals Holding AB (publ)
Healthcare|BiotechnologySTO
$0.56+3.72%
+$0.02 (+3.72%) • Jun 12
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.87
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.61
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INDEX.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.55 – $0.56
TARGET (TP)$0.64
STOP LOSS$0.51
RISK/REWARD1:1.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.21
52W High$0.93
52W Low$0.20
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $97.50M | $1.15M | $440,000 | $35,000 | $88,000 |
| Gross Profit | $-95,708,000 | $-9,141,000 | $-13,943,000 | $-15,986,000 | $-3,815,000 |
| Gross Margin | -98.2% | -797.6% | -3168.9% | -45674.3% | -4335.2% |
| Operating Income | $-95,708,000 | $-103,227,000 | $-102,910,000 | $-57,349,000 | $-87,712,000 |
| Net Income | $-95,265,000 | $-97,439,000 | $-103,176,000 | $-57,531,000 | $-87,834,000 |
| Net Margin | -97.7% | -8502.5% | -23449.1% | -164374.3% | -99811.4% |
| EPS | $-0.18 | $-0.18 | $-0.21 | $-0.24 | $-0.45 |
Company Overview
InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in preclinical stage for the treatment of various immunological diseases. The company was founded in 2000 and is headquartered in Solna, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
INDEX.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.01
Q2 2024
EPS Surprise History
Q3 22
No data
Q4 22
No data
Q1 23
No data
Q2 23
No data
Q3 23
No data
Q4 23
No data
Q1 24
No data
Q2 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | Apr 26, 2024 | — | $-0.01 | — | — |
Q1 2024 | Feb 21, 2024 | — | $-0.20 | — | — |
Q4 2023 | Nov 28, 2023 | — | $-0.07 | — | — |
Q3 2023 | Aug 23, 2023 | — | $0.17 | — | — |
Q2 2023 | May 24, 2023 | — | $-0.07 | — | — |
Q1 2023 | Feb 23, 2023 | — | $-0.10 | — | — |
Q4 2022 | Nov 23, 2022 | — | $-0.00 | — | — |
Q3 2022 | Aug 26, 2022 | — | $-0.04 | — | — |
Q2 2022 | May 16, 2022 | — | $-0.04 | — | — |
Q1 2022 | Feb 23, 2022 | — | $-0.04 | — | — |
Q4 2021 | Oct 28, 2021 | — | $-0.05 | — | — |
Q3 2021 | Aug 25, 2021 | — | $-0.08 | — | — |
Q2 2021 | May 5, 2021 | — | $-0.02 | — | — |
Q1 2021 | Feb 25, 2021 | — | $-0.04 | — | — |
Q4 2020 | Nov 25, 2020 | — | $-0.03 | — | — |
Q3 2020 | Aug 26, 2020 | — | $-0.07 | — | — |
Q2 2020 | May 7, 2020 | — | $-0.10 | — | — |
Q1 2020 | Feb 20, 2020 | — | $-0.14 | — | — |
Q4 2019 | Nov 27, 2019 | — | $-0.15 | — | — |
Q3 2019 | Aug 15, 2019 | — | $-0.10 | — | — |
Latest News
Loading news...
Frequently Asked Questions about INDEX.ST
What is INDEX.ST's current stock price?
InDex Pharmaceuticals Holding AB (publ) (INDEX.ST) is currently trading at $0.56 per share. The stock has moved +3.72% today.
What is the analyst price target for INDEX.ST?
No analyst price targets are currently available for this stock.
What sector is InDex Pharmaceuticals Holding AB (publ) in?
InDex Pharmaceuticals Holding AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is INDEX.ST's market cap?
InDex Pharmaceuticals Holding AB (publ) has a market capitalization of $3.69 billion, making it a mid-cap company.
Does INDEX.ST pay dividends?
No, InDex Pharmaceuticals Holding AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABLI.ST
Abliva AB (publ)
$0.44
Mkt Cap: $0.7B
AMNI.ST
Amniotics AB (publ)
$0.01
Mkt Cap: $0.0B
COMBI.ST
CombiGene AB (publ)
$2.47
Mkt Cap: $0.0B
CYXO.ST
Cyxone AB (publ)
$0.02
Mkt Cap: $0.0B
ISR.ST
ISR Immune System Regulation Holding AB (publ)
$1.40
Mkt Cap: $0.1B
KAN.ST
Kancera AB (publ)
$0.30
Mkt Cap: $0.0B
MVIR-B.ST
Medivir AB (publ)
$7.22
Mkt Cap: $0.4B
PROB.ST
Probi AB (publ)
$348.00
Mkt Cap: $4.0B
PROMO.ST
Promore Pharma AB (publ)
$0.11
Mkt Cap: $0.3B
SCOL.ST
Scandion Oncology A/S
$0.00
Mkt Cap: $0.0B
Explore stocks similar to INDEX.ST for comparison